A detailed history of Quantbot Technologies LP transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Quantbot Technologies LP holds 704 shares of NTLA stock, worth $7,645. This represents 0.0% of its overall portfolio holdings.

Number of Shares
704
Holding current value
$7,645
% of portfolio
0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 11, 2025

BUY
$11.41 - $21.09 $8,032 - $14,847
704 New
704 $8,000
Q3 2022

Nov 07, 2022

SELL
$53.92 - $71.7 $387,415 - $515,164
-7,185 Reduced 83.42%
1,428 $79,000
Q2 2022

Aug 09, 2022

BUY
$38.49 - $76.21 $331,514 - $656,396
8,613 New
8,613 $445,000
Q4 2021

Feb 11, 2022

SELL
$100.76 - $138.36 $340,568 - $467,656
-3,380 Closed
0 $0
Q3 2021

Nov 09, 2021

BUY
$132.37 - $176.78 $447,410 - $597,516
3,380 New
3,380 $453,000
Q1 2021

May 14, 2021

SELL
$46.59 - $83.68 $21,151 - $37,990
-454 Closed
0 $0
Q4 2020

Feb 12, 2021

BUY
$18.83 - $63.53 $8,548 - $28,842
454 New
454 $24,000
Q2 2020

Aug 13, 2020

SELL
$11.14 - $22.87 $222 - $457
-20 Closed
0 $0
Q1 2020

May 13, 2020

SELL
$9.44 - $15.58 $35,296 - $58,253
-3,739 Reduced 99.47%
20 $0
Q4 2019

Feb 10, 2020

SELL
$10.43 - $17.67 $17,532 - $29,703
-1,681 Reduced 30.9%
3,759 $55,000
Q3 2019

Nov 12, 2019

BUY
$13.07 - $18.51 $58,030 - $82,184
4,440 Added 444.0%
5,440 $72,000
Q2 2019

Aug 13, 2019

BUY
$13.88 - $18.41 $13,880 - $18,410
1,000 New
1,000 $16,000
Q3 2018

Nov 13, 2018

SELL
$25.78 - $32.6 $38,824 - $49,095
-1,506 Closed
0 $0
Q2 2018

Aug 13, 2018

BUY
$20.02 - $30.79 $4,404 - $6,773
220 Added 17.11%
1,506 $41,000
Q1 2018

May 11, 2018

BUY
$19.43 - $34.95 $5,751 - $10,345
296 Added 29.9%
1,286 $27,000
Q4 2017

Feb 12, 2018

BUY
$17.39 - $31.12 $17,216 - $30,808
990
990 $19,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $825M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Quantbot Technologies LP Portfolio

Follow Quantbot Technologies LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quantbot Technologies LP, based on Form 13F filings with the SEC.

News

Stay updated on Quantbot Technologies LP with notifications on news.